View : 71 Download: 0
A prospective randomized controlled trial to determine the safety and efficacy of extracorporeal shock waves therapy for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin
- Title
- A prospective randomized controlled trial to determine the safety and efficacy of extracorporeal shock waves therapy for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin
- Authors
- Song; Shinjeong; Woo; Joohyun; Kim; HyunGoo; Lee; Jun Woo; Lim; Woosung; Moon; Byung-In; Kwon; Kihwan
- Ewha Authors
- 문병인; 권기환; 임우성; 우주현; 이준우; 김현구; 송신정
- SCOPUS Author ID
- 문병인
![scopus](/images/layout/icon2.png)
; 권기환
; 임우성
; 우주현
; 이준우![scopus](/images/layout/icon2.png)
; 김현구![scopus](/images/layout/icon2.png)
![scopus](/images/layout/icon2.png)
![scopus](/images/layout/icon2.png)
- Issue Date
- 2024
- Journal Title
- Frontiers in Cardiovascular Medicine
- ISSN
- 2297-055X
- Citation
- Frontiers in Cardiovascular Medicine vol. 11
- Keywords
- breast cancer; cancer therapy-related cardiac dysfunction; cardiac extracorporeal shock wave therapy; doxorubicin; left ventricular global longitudinal strain/LV GLS
- Publisher
- Frontiers Media SA
- Indexed
- SCIE; SCOPUS
![scopus](/images/layout/scopus2.gif)
- Document Type
- Article
- Abstract
- Background: Doxorubicin is a highly effective anti-cancer drug that causes left ventricular (LV) dysfunction and induces late-onset cardiomyopathy. However, an effective and clinically applicable preventive treatment is yet to be discovered. Objective: Cardiac-Extracorporeal shockwave therapy (C-ESWT) has been suggested to treat inflammatory and ischemic diseases and protect cardiomyocytes from doxorubicin-induced cardiomyopathy. This study aims to assess the safety and efficacy of C-ESWT in the prevention of subclinical cardiotoxicity. Methods: We enrolled 64 breast cancer patients. C-ESWT group 33 patients were treated with our C-ESWT (200 shots/spot at 0.09 mJ/mm2 for 20 spots, 3 times every six weeks). The efficacy endpoints were the difference in left ventricular global longitudinal strain (LVGLS) change by 2D speckle tracking echocardiography and chemotherapy-related cardiac dysfunction (CTRCD). Echocardiography was performed on the baseline line and every 4 cycles of chemotherapy, followed by a follow-up 3,6 months after chemotherapy to compare the incidence of cardiomyopathy of subclinical LV dysfunction due to chemotherapy between the two groups. Results: Participants averaged 50 ± 9 years in age, 100% female. In the results of follow-up 6 months after the end of chemotherapy, there was a significant difference in delta LVGLS between the C-ESWT group and the control group (LVGLS; −1.1 ± 10.9% vs. −11.5 ± 11.6% p-value; <0.001). A total of 23% (15 patients) of patients developed CTRCD (Control group; 13 vs. C-ESWT group; (2). C-ESWT was performed safely without any serious adverse events. Conclusion: In this prospective study, C-ESWT established efficacy in preventing subclinical cardiotoxicity, especially in breast cancer patients using doxorubicin chemotherapy, and the safety of C-ESWT. Clinical Trial Registration: ClinicalTrials.gov, identifier (NCT05584163). 2024 Song, Woo, Kim, Lee, Lim, Moon and Kwon.
- DOI
- 10.3389/fcvm.2024.1324203
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML